Point72 Europe (London) LLP Blueprint Medicines Corp Transaction History
Point72 Europe (London) LLP
- $1.48 Billion
- Q3 2024
Shares
1 transactions
Others Institutions Holding BPMC
# of Institutions
350Shares Held
60.3MCall Options Held
2.25MPut Options Held
1.18M-
Vanguard Group Inc Valley Forge, PA6.68MShares$632 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.65MShares$629 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.39MShares$510 Million0.06% of portfolio
-
Wellington Management Group LLP Boston, MA3.96MShares$375 Million0.07% of portfolio
-
State Street Corp Boston, MA2.77MShares$262 Million0.01% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $5.65B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...